Skip to main content
SPTX logo

SPTX · Seaport Therapeutics, Inc. · Documents

Track SPTX — free
$18.14 -0.18 (-0.96%)
Market Cap
$980.14M
Shares
53.53M
Volume · Nov 19 63.59K Avg daily vol (3M) 252.84K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Quarterly report FY2026 Q3 Net loss $26.39M 10-Q filed Nov 2, 2026 Latest results Q3 Net Loss $26.4 Million; Cash Funds Operations Into 2029 8-K filed Nov 2, 2026
2026
Nov 10
Investor event
Cash runway into 2029 supports upcoming readouts

Seaport Therapeutics ended Q3 with just north of $403 million, providing runway into 2029 ahead of a Glyph Allo top-line readout in the first half of 2027 and a Glyph-Ago Phase 2A readout in early 2028.

3 source passages
Seaport Therapeutics ended Q3 with just north of $403 million on our balance sheet. That provides us runway into 2029, and as mentioned earlier, we covered three upcoming key clinical readouts. Our lead program, Glyph Allo, is currently in a Phase 2B potential registration-enabling study in MDD. Our second program, Glyph-Ago, we recently shared key proof-of-concept data, and we just dosed our patient in a Phase IIa trial in generalized anxiety disorder. We get through our top-line readout of our current trial in glyph-allo-buy one. That's in the first half of 2027, and then we move into our second program, glyph-ago. We get our Phase 2A readout in early 2028 and our Phase 2-3 potentially registration-enabling trial at the end of 2028. Open the document at this passage
Nov 2
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash runway extends into 2029 after IPO

Seaport Therapeutics reported a $114.4 million nine-month net loss and $403.8 million in cash, cash equivalents and investments, which management believes will fund operations into 2029 after its IPO.

Net loss $26.39M Diluted EPS -$0.49
Read from the MD&A section
3 source passages
During the nine months ended September 30, 2026 and 2025, we had a net loss of $114.4 million and $50.7 million, respectively. As of September 30, 2026, we had cash, cash equivalents and investments of $403.8 million. Based on our current operating plans, we believe that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements into 2029. Open the document at this passage
Nov 2
Current report 8-K
Q3 Net Loss $26.4 Million; Cash Funds Operations Into 2029

Seaport Therapeutics reported a third-quarter 2026 net loss of $26.4 million, versus $22.5 million a year earlier. Cash, cash equivalents and investments totaled $403.8 million at September 30, 2026, expected to fund operations into 2029.

Financial results
3 source passages
Net loss was $26.4 million for the third quarter of 2026, as compared to a net loss of $22.5 million for the third quarter of 2025. Cash, cash equivalents, and investments totaled $403.8 million as of September 30, 2026. Seaport expects its cash, cash equivalents, and investments to support its current operating plans into 2029. Open the document at this passage
Showing 1–12 of 12 documents
Key facts CIK 2042347 CUSIP 81221K108 13F (30d) 73 filings 73 filers Visit website Investor relations